Low molecular weight heparins: Background and pharmacology

Seminars in Respiratory and Critical Care Medicine

Volumn 21, Issue 6, 2000, Pages 537-546

  Morris, T A ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Deep venous thrombosis; Heparin; Low molecular weight heparin; Pulmonary embolism

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; BLOOD CLOT LYSIS; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOSIS;

EID: 0034527551     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-13185     Document Type: Review

References (64)

1. Production and chemical processing of low molecular weight heparins
2. Structural characterization of low molecular weight heparins
3. In vitro studies on the biochemistry and pharmacology of low molecular weight heparin
4. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin
5. Risk factors for bleeding during treatment of acute venous thromboembolism
6. Shortened hospitalization by means of adjusted-dose subcutaneous heparin for deep venous thrombosis
7. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis
8. Low molecular weight heparin
9. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits
10. A meta-analysis comparing low-molecular-weight heparin with unfractionated heparin in the treatment of venous thromboembolism
11. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin: A three way cross over study in human volunteers
12. Anticoagulant, thrombolytic and antiplatelet drugs
13. Factor Xa inhibition: Correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage
14. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins
15. Treatment doses of different low molecular weight heparins and unfractionated heparins differ in their anticoagulating effects in respect to aPTT, Heptest, anti-IIa- and anti-Xa-activity
16. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor
17. Heparin
18. Guide to anticoagulant therapy. Part 1: Heparin
19. On the relationship between molecular mass and anticoagulant activity in a low molecular weight heparin (enoxaparin)
20. The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction
21. Evidence that meizothrombin is an intermediate product in the clotting of whole blood
22. The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma
23. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs)
24. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis
25. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4)
26. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: Platelet factor 4
27. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
28. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor Xa activity as a pharmaceutical mechanism and a yardstick for therapy
29. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: Inter-assay variability
30. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin
31. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots
32. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator
33. Are the available low-molecular-weight heparin preparations the same?
34. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin
35. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects
36. Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C
37. Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C
38. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit
39. A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit
40. Ability of low molecular weight heparin to inhibit propagation of deep venous thrombosis
41. American Thoracic Society Position Paper: The diagnostic approach to acute venous thromboembolism
42. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
43. Prophylactically equivalent doses of enoxaprin and unfractionated heparin inhibit in vivo coagulation to the same extent
44. D-dimer testing and acute venous thromboembolism. A shortcut to accurate diagnosis?
45. The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men
46. Markers of hemostatic system activation in acute deep venous thrombosis: Evolution during the first days of heparin treatment
47. Diagnostic value of fibrinopeptide A and beta-thromboglobulin in acute deep venous thrombosis and pulmonary embolism
48. Diagnostic and prognostic value of fibrinopeptides in patients with clinically suspected pulmonary embolism
49. Fibrinopeptide A levels in primary pulmonary hypertension
50. Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina
51. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state
52. Comparison of immunological and functional assays for measurement of soluble fibrin
53. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials
54. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
55. Treatment of deep venous thrombosis with low-molecular-weight heparins: A meta-analysis
56. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
57. Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo: Studies of venous and arterial thrombosis
58. Structural features and bleeding activity of commercial low molecular weight heparins: Neutralization by ATP and protamine
59. Pharmacokinetics of low molecular weight heparins in animal models
60. Human pharmacokinetics of low molecular weight heparins
61. Preclinical differentiation of low molecular weight heparins
62. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis
63. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial
64. Recurrent venous thrombosis and heparin therapy: An evaluation of the importance of early activated partial thromboplastin times